Beckley Psytech has divulged ergoline analogues acting as 5-HT2A and/or 5-HT2B and/or 5-HT2C receptor agonists reported to be useful for the treatment of depression.
Chengdu Baiyu Pharmaceutical has presented pyrimidine derivatives acting as GTPase KRAS (Gly12Cys mutant) inhibitors reported to be useful for the treatment of cancer.
Monte Rosa Therapeutics has synthesized new proteolysis targeting chimera (PROTAC) compounds comprising a protein cereblon (CRBN) binding moiety covalently linked to a eukaryotic peptide chain release factor GTP-binding subunit ERF3A (GSPT1)-targeting moiety reported to be useful for the treatment of cancer.
The National Institute of Pharmaceutical R&D (Beijing) has described bridged heterocyclyl-substituted pyrimidine compounds acting as tyrosine-protein kinase JAK-1 and/or non-receptor tyrosine-protein kinase TYK2 inhibitors reported to be useful for the treatment of inflammation, autoimmune disease and cancer.
GlaxoSmithKline has divulged mas-related G protein-coupled receptor member X2 (MRGPRX2) antagonists reported to be useful for the treatment of osteoarthritis, migraine, asthma, irritable bowel syndrome, atopic dermatitis, psoriasis, urticaria and rheumatoid arthritis, among other disorders.
A University of Texas MD Anderson Cancer Center-based research team demonstrated that Col1 produced by pancreatic cancer cells is an oncogenic homotrimer variant (a1/a1/a1) instead of the normal Col1 heterotrimer (a1/a2/a1) produced by fibroblasts.
Researchers from University of Miami Miller School of Medicine reported preclinical data for ZyVersa Therapeutics' novel humanized IgG4 monoclonal antibody targeting apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC), named IC-100.
HDT Bio has been awarded a nearly USD 1.8 million grant from the U.S. Army Medical Research Acquisition Activity to develop HDT-201 into an antiviral intranasal spray that can stimulate the body's innate immune system to treat and prevent a broad spectrum of deadly human viruses.